OMRF brain tumor drug receives rare disease designations from the FDA

Published: Thursday, September 3, 2020 By: Adam Kemp Source: NewsOK

A “game changing” drug for treating two different types of cancer has been given the green light by the U.S. Food and Drug Administration.

OKN-007, an investigation drug discovered at the Oklahoma Medical Research Foundation, was awarded “Rare Pediatric Disease Designation” by the FDA for treatment against diffuse intrinsic pontine glioma and “Orphan Drug Designation” for treatment of malignant glioma.

Diffuse intrinsic pontine glioma is a fast-growing pediatric cancer that starts in the brain stem and currently has no effective treatments, according to Dr. Rheal Towner, an OMRF scientist.

It is one of several sub-categories of malignant gliomas, deadly cancers of the brain and spinal cord.

Read the story on

Back to top